462 related articles for article (PubMed ID: 30293945)
1. First-in-man Safety and Efficacy of the ClearRing Implant for the Treatment of Benign Prostatic Hyperplasia.
Vjaters E; Nitsan D; Mullerad M; Engelstein D; Leibovitch I; Feld Y
Eur Urol Focus; 2020 Jan; 6(1):131-136. PubMed ID: 30293945
[TBL] [Abstract][Full Text] [Related]
2. Temporary implantable nitinol device (TIND): a novel, minimally invasive treatment for relief of lower urinary tract symptoms (LUTS) related to benign prostatic hyperplasia (BPH): feasibility, safety and functional results at 1 year of follow-up.
Porpiglia F; Fiori C; Bertolo R; Garrou D; Cattaneo G; Amparore D
BJU Int; 2015 Aug; 116(2):278-87. PubMed ID: 25382816
[TBL] [Abstract][Full Text] [Related]
3. Minimally invasive prostatic urethral lift: surgical technique and multinational experience.
McNicholas TA; Woo HH; Chin PT; Bolton D; Fernández Arjona M; Sievert KD; Schoenthaler M; Wetterauer U; Vrijhof EJ; Gange S; Montorsi F
Eur Urol; 2013 Aug; 64(2):292-9. PubMed ID: 23357348
[TBL] [Abstract][Full Text] [Related]
4. Second-generation of temporary implantable nitinol device for the relief of lower urinary tract symptoms due to benign prostatic hyperplasia: results of a prospective, multicentre study at 1 year of follow-up.
Porpiglia F; Fiori C; Amparore D; Kadner G; Manit A; Valerio M; Nicolaas L; Ho BSH; Alonso S; Schulman C; Barber N
BJU Int; 2019 Jun; 123(6):1061-1069. PubMed ID: 30382600
[TBL] [Abstract][Full Text] [Related]
5. Urinary and sexual function after treatment with temporary implantable nitinol device (iTind) in men with LUTS: 6-month interim results of the MT-06-study.
De Nunzio C; Cantiello F; Fiori C; Crocerossa F; Tognoni P; Amparore D; Baldassarri V; Elbers JR; Sancha FG; Porpiglia F
World J Urol; 2021 Jun; 39(6):2037-2042. PubMed ID: 32851439
[TBL] [Abstract][Full Text] [Related]
6. Minimally invasive prostatic urethral lift (PUL) efficacious in TURP candidates: a multicenter German evaluation after 2 years.
Sievert KD; Schonthaler M; Berges R; Toomey P; Drager D; Herlemann A; Miller F; Wetterauer U; Volkmer B; Gratzke C; Amend B
World J Urol; 2019 Jul; 37(7):1353-1360. PubMed ID: 30283994
[TBL] [Abstract][Full Text] [Related]
7. 3-Year follow-up of temporary implantable nitinol device implantation for the treatment of benign prostatic obstruction.
Porpiglia F; Fiori C; Bertolo R; Giordano A; Checcucci E; Garrou D; Cattaneo G; De Luca S; Amparore D
BJU Int; 2018 Jul; 122(1):106-112. PubMed ID: 29359881
[TBL] [Abstract][Full Text] [Related]
8. Second generation of temporary implantable nitinol device (iTind) in men with LUTS: 2 year results of the MT-02-study.
Kadner G; Valerio M; Giannakis I; Manit A; Lumen N; Ho BSH; Alonso S; Schulman C; Barber N; Amparore D; Porpiglia F
World J Urol; 2020 Dec; 38(12):3235-3244. PubMed ID: 32124019
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and Safety of Rezūm System Water Vapor Treatment for Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia.
Dixon C; Cedano ER; Pacik D; Vit V; Varga G; Wagrell L; Tornblom M; Mynderse L; Larson T
Urology; 2015 Nov; 86(5):1042-7. PubMed ID: 26216644
[TBL] [Abstract][Full Text] [Related]
10. Randomised Clinical Trial of Prostatic Artery Embolisation Versus a Sham Procedure for Benign Prostatic Hyperplasia.
Pisco JM; Bilhim T; Costa NV; Torres D; Pisco J; Pinheiro LC; Oliveira AG
Eur Urol; 2020 Mar; 77(3):354-362. PubMed ID: 31831295
[TBL] [Abstract][Full Text] [Related]
11. Five-year outcomes for Aquablation therapy compared to TURP: results from a double-blind, randomized trial in men with LUTS due to BPH.
Gilling PJ; Barber N; Bidair M; Anderson P; Sutton M; Aho T; Kramolowsky E; Thomas A; Kaufman RP; Badlani G; Plante M; Desai M; Doumanian L; Te AE; Roehrborn CG
Can J Urol; 2022 Feb; 29(1):10960-10968. PubMed ID: 35150215
[TBL] [Abstract][Full Text] [Related]
12. Usage of GreenLight HPS 180-W laser vaporisation for treatment of benign prostatic hyperplasia.
Jovanović M; Džamić Z; Aćimović M; Kajmaković B; Pejčić T
Acta Chir Iugosl; 2014; 61(1):57-61. PubMed ID: 25782227
[TBL] [Abstract][Full Text] [Related]
13. The prostatic urethral lift for the treatment of lower urinary tract symptoms associated with prostate enlargement due to benign prostatic hyperplasia: the L.I.F.T. Study.
Roehrborn CG; Gange SN; Shore ND; Giddens JL; Bolton DM; Cowan BE; Brown BT; McVary KT; Te AE; Gholami SS; Rashid P; Moseley WG; Chin PT; Dowling WT; Freedman SJ; Incze PF; Coffield KS; Borges FD; Rukstalis DB
J Urol; 2013 Dec; 190(6):2161-7. PubMed ID: 23764081
[TBL] [Abstract][Full Text] [Related]
14. The EXPANDER-1 trial: introduction of the novel Urocross™ Expander System for treatment of lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH).
Woo HH; Huang CP; Huang WJ; Chang YH; Lien CS; Chkhotua A; Elterman DS
Prostate Cancer Prostatic Dis; 2022 Sep; 25(3):576-582. PubMed ID: 35641601
[TBL] [Abstract][Full Text] [Related]
15. Prospective, randomized, multinational study of prostatic urethral lift versus transurethral resection of the prostate: 12-month results from the BPH6 study.
Sønksen J; Barber NJ; Speakman MJ; Berges R; Wetterauer U; Greene D; Sievert KD; Chapple CR; Montorsi F; Patterson JM; Fahrenkrug L; Schoenthaler M; Gratzke C
Eur Urol; 2015 Oct; 68(4):643-52. PubMed ID: 25937539
[TBL] [Abstract][Full Text] [Related]
16. Prostatic Artery Embolisation Versus Transurethral Resection of the Prostate for Benign Prostatic Hyperplasia: 2-yr Outcomes of a Randomised, Open-label, Single-centre Trial.
Abt D; Müllhaupt G; Hechelhammer L; Markart S; Güsewell S; Schmid HP; Mordasini L; Engeler DS
Eur Urol; 2021 Jul; 80(1):34-42. PubMed ID: 33612376
[TBL] [Abstract][Full Text] [Related]
17. Prostate Artery Embolization for Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia: Results From a Prospective FDA-Approved Investigational Device Exemption Study.
Salem R; Hairston J; Hohlastos E; Riaz A; Kallini J; Gabr A; Ali R; Jenkins K; Karp J; Desai K; Thornburg B; Casalino D; Miller F; Hofer M; Hamoui N; Mouli S
Urology; 2018 Oct; 120():205-210. PubMed ID: 30036614
[TBL] [Abstract][Full Text] [Related]
18. A comparative randomized prospective study to evaluate efficacy and safety of combination of tamsulosin and tadalafil vs. tamsulosin or tadalafil alone in patients with lower urinary tract symptoms due to benign prostatic hyperplasia.
Singh DV; Mete UK; Mandal AK; Singh SK
J Sex Med; 2014 Jan; 11(1):187-96. PubMed ID: 24165272
[TBL] [Abstract][Full Text] [Related]
19. What's New in TIND?
Marcon J; Magistro G; Stief CG; Grimm T
Eur Urol Focus; 2018 Jan; 4(1):40-42. PubMed ID: 29705283
[TBL] [Abstract][Full Text] [Related]
20. Temporary implantable nitinol device for benign prostatic hyperplasia-related lower urinary tract symptoms: over 48-month results.
Amparore D; De Cillis S; Schulman C; Kadner G; Fiori C; Porpiglia F
Minerva Urol Nephrol; 2023 Dec; 75(6):743-751. PubMed ID: 37350585
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
